Skip to main content
Premium Trial:

Request an Annual Quote

Early Glimpse

Early results from a gene-editing trial suggest that the treatment may be working, the Associated Press reports.

In its Phase 1/2 CHAMPIONS Study, Sangamo Therapeutics is examining an in vivo genome editing treatment for Hunter syndrome, a condition marked by the accumulation of glycosaminoglycans, which leads to the enlargement of organs, tissue damage, and more. In particular, patients in the trial were given low, medium, or high doses of SB-913, a zinc-finger-based genome editing therapy that aims to insert a functional copy of the IDS gene that is affected in patients.

As the AP reports, the two patients given the medium dose saw drops in their urine glycosaminoglycans levels — after four months, they experienced an average 51 percent decline in glycosaminoglycans. The low-dose patients, however, saw a rise in glycosaminoglycans, and the high-dose patients are still being evaluated. Still, the AP says these results may be cause for cautious optimism.

"This is not proof that this is a successful therapy yet, that these patients had enough gene editing to now supply them with the enzyme they need for the rest of their life," the University of North Carolina, Chapel Hill's Joseph Muenzer, who leads the study, tells the AP. He adds, though, that the treatment appears safe.

The trial includes Brian Madeux, who was the first to undergo the treatment, the AP notes.

The Scan

Genetic Ancestry of South America's Indigenous Mapuche Traced

Researchers in Current Biology analyzed genome-wide data from more than five dozen Mapuche individuals to better understand their genetic history.

Study Finds Variants Linked to Diverticular Disease, Presents Polygenic Score

A new study in Cell Genomics reports on more than 150 genetic variants associated with risk of diverticular disease.

Mild, Severe Psoriasis Marked by Different Molecular Features, Spatial Transcriptomic Analysis Finds

A spatial transcriptomics paper in Science Immunology finds differences in cell and signaling pathway activity between mild and severe psoriasis.

ChatGPT Does As Well As Humans Answering Genetics Questions, Study Finds

Researchers in the European Journal of Human Genetics had ChatGPT answer genetics-related questions, finding it was about 68 percent accurate, but sometimes gave different answers to the same question.